<DOC>
	<DOCNO>NCT00616967</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may stop growth tumor cell block enzymes need cell growth . Vorinostat may also help carboplatin paclitaxel albumin-stabilized nanoparticle formulation work well make tumor cell sensitive drug . Giving chemotherapy without vorinostat surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This randomized phase II trial study well give carboplatin together paclitaxel albumin-stabilized nanoparticle formulation work without vorinostat treat woman breast cancer remove surgery .</brief_summary>
	<brief_title>Carboplatin Nab-Paclitaxel With Without Vorinostat Treating Women With Newly Diagnosed Operable Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine pathological complete response ( pCR ) rate patient HER2-negative primary operable breast cancer treat neoadjuvant therapy comprise carboplatin paclitaxel albumin-stabilized nanoparticle formulation ( CP ) v without vorinostat . Secondary - To evaluate safety regimens patient . - To estimate clinical complete response ( cCR ) rate patient treat regimen . - To correlate baseline change ( day 15 ) surrogate uptake value ( SUV ) FDG-PET pathological clinical response patient treat regimen , determine percent woman ≥ 25 % ≥ 50 % reduction SUV day 15 achieve pCR cCR CP v without vorinostat . - To correlate baseline change marker proliferation pathological clinical response patient treat regimen . - To evaluate long term outcome ( e.g. , recurrence breast cancer , development new cancer , death ) patient treat regimen . Tertiary - To evaluate baseline change candidate gene methylation expression profile . - To evaluate baseline change tissue peripheral blood mononuclear cell histone acetylation . - To compare cCR pCR woman basal-like feature versus subtypes . OUTLINE : This multicenter , randomize , double-blind , phase II study ( primary study portion ) 6-12 patient run-in portion . - Run-in portion : Patients receive carboplatin IV paclitaxel albumin-stabilized nanoparticle formulation IV day 1 oral vorinostat day 1-3 . Treatment repeat weekly 12 week absence disease progression unacceptable toxicity . Once safety combination chemotherapy vorinostat confirm , subsequently enrol patient enter primary study portion . - Primary study portion : Patients stratify hormone receptor status ( estrogen receptor [ ER ] -negative progesterone receptor [ PR ] -negative v ER-positive and/or PR-positive ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carboplatin IV paclitaxel albumin-stabilized nanoparticle formulation IV day 1 oral placebo day 1-3 . Treatment repeat weekly 12 week absence disease progression unacceptable toxicity . - Arm II : Patients receive carboplatin paclitaxel albumin-stabilized nanoparticle formulation arm I oral vorinostat day 1-3 . Treatment repeat weekly 12 week absence disease progression unacceptable toxicity . Within 2-4 week completion neoadjuvant chemotherapy , patient undergo breast conserve surgery mastectomy discretion treat physician . Patients undergo tumor tissue biopsy baseline , day 15 , time definitive surgery . Samples analyze immunohistochemistry ( IHC ) , RNA extraction , gene expression analysis use RT-PCR identify candidate marker response molecular profile may relevant understanding drug mechanism . Methylation relevant gene ( e.g. , ERalpha , APC-1 , RARbeta , cyclin D2 , Twist , RASSF1A , HIN-1 ) evaluate quantitative multiplex methylation-specific PCR . Changes gene expression result treatment determine IHC quantitative RT-PCR . Blood sample collect baseline , day 15 , time definitive surgery , 4 week surgery DNA methylation study , pharmacogenomic study , histone acetylation assay . Patients also undergo fludeoxyglucose F 18-positron emission tomography ( FDG-PET ) PET/CT baseline day 15 ass treatment response measure standardized uptake value . After completion study treatment , patient follow every 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm infiltrate ductal breast cancer core needle biopsy Mixed ductal lobular disease allow Infiltrating lobular cancer allow runin portion Unresected , clinically measurable disease , meet 1 follow clinical stag criterion : T2 , T3 , T4 lesion , N , M0 T1c , N13 , M0 Patients skin metastasis ipsilateral breast chemotherapy plan prior definitive surgery eligible primary study portion HER2negative disease Hormone receptor status* meet 1 follow criterion : Estrogen receptor ( ER ) negative progesterone receptor ( PR ) negative ERpositive ( grade II III ) PRpositive PRnegative NOTE : *Any ER PR status runin portion PATIENT CHARACTERISTICS : ECOG performance status 01 Menopausal status specify ANC ≥ 1,500/mm³ Platelet count ≥ 150,000/mm³ Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 50 mL/min Total bilirubin normal AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ( ULN ) alkaline phosphatase ≤ 2.5 time ULN PT INR ≤ 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) PTT ≤ ULN Adequate cardiac function define evidence PR prolongation AV block baseline electrocardiogram ( ECG ) Willing use effective , nonhormonal contraception treatment least 3 month thereafter Not pregnant nursing No preexist peripheral neuropathy ≥ grade 2 No history severe hypersensitivity reaction drug formulate polysorbate 80 E. coliderived product No history allergic reaction attribute compound similar chemical biologic composition vorinostat No medical condition , opinion investigator , put patient risk potentially serious complication therapy PRIOR CONCURRENT THERAPY : At least 4 week since prior valproic acid histone deacetylase inhibitor No prior chemotherapy , radiotherapy , endocrine therapy cancer Prior tamoxifen raloxifene another agent prevention breast cancer allow long patient discontinue treatment ≥ 1 month prior baseline study biopsy No systemic treatment prior cancer within past 5 year ( primary study portion ) No prior ongoing systemic treatment cancer ( primary study portion ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent histone deacetylase inhibitor No concurrent chemotherapy , antiestrogen therapy , radiotherapy , investigational systemic therapy No concurrent biologic therapy No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>ductal breast carcinoma</keyword>
	<keyword>lobular breast carcinoma</keyword>
</DOC>